Point72 Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Point72 Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$59.3K	Buy	47,054 +517	+1%	+$653	﹤0.01%	3650
2025 Q4	$56.8K	Sell	46,537 -4,291,857	-99%	-$6.45M	﹤0.01%	3783
2025 Q3	$6.42M	Buy	+4,338,394	New	+$6.62M	0.01%	971
2023 Q2	–	Sell	-9,697	Closed	-$258K	–	2648
2023 Q1	$258K	Buy	+9,697	New	+$276K	﹤0.01%	1403
2022 Q3	–	Sell	-484,524	Closed	-$3.88M	–	1667
2022 Q2	$3.88M	Sell	484,524 -285,476	-37%	-$1.83M	0.02%	774
2022 Q1	$5.4M	Sell	770,000 -365,100	-32%	-$3.73M	0.02%	686
2021 Q4	$15.3M	Buy	+1,135,100	New	+$18M	0.06%	399
2020 Q4	–	Sell	-51,500	Closed	-$1.17M	–	1083
2020 Q3	$1.17M	Buy	+51,500	New	+$1.29M	0.01%	761

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Point72 Asset Management's PLRX Position: Q1 2026 in Review

Point72 Asset Management increased its Pliant Therapeutics (PLRX) stake by 1.1% in Q1 2026, buying an estimated $653 and bringing the position to 47,054 shares worth $59.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

Point72 Asset Management first reported a position in PLRX in Q3 2020 and has held it in 8 quarters since. The position peaked at $15.3M in Q4 2021. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

Point72 Asset Management held 47,054 shares of Pliant Therapeutics worth $59.3K as of Q1 2026.
Point72 Asset Management bought 517 Pliant Therapeutics shares in Q1 2026, an estimated $653.
Pliant Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3650 holding.
Point72 Asset Management first reported a position in Pliant Therapeutics in Q3 2020 and has held it in 8 quarters since.
Point72 Asset Management's Pliant Therapeutics position peaked at $15.3M in Q4 2021.
91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.